Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.55 |
| ▸ | STAT1 | P42224 | 1/20 | 0.55 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | WEE1 | P30291 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9764318 | 0.90 | STAT3 (0.58) | STAT3STAT1KDM4ENPC1ALDH1A1 | |
| SCHEMBL4510674 | 0.84 | STAT3 (0.46) | STAT3STAT1 | |
| SCHEMBL17112278 | 0.83 | STAT3 (0.55) | STAT3STAT1FFAR1 | |
| SCHEMBL9386118 | 0.82 | NUDT1 (0.43) | STAT3STAT1NUDT1FFAR1KDM4E | |
| SCHEMBL14720188 | 0.81 | STAT3 (0.56) | STAT3STAT1 | |
| SCHEMBL11328879 | 0.81 | STAT3 (0.56) | STAT3STAT1KDM4EGAA | |
| SCHEMBL3289548 | 0.81 | NUDT1 (0.45) | NUDT1 | |
| SCHEMBL19407291 | 0.80 | STAT3 (0.74) | STAT3STAT1KDM4ENPC1ALDH1A1 | |
| SCHEMBL7269032 | 0.80 | STAT3 (0.58) | STAT3STAT1 | |
| SCHEMBL2849607 | 0.80 | STAT3 (0.58) | STAT3STAT1KDM4ENPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040116500-A1 | Methods and compositions to treat lung diseases | SAKALOSKY GEORGE P (US) | 2004-06-17 | — | — | US | disclosed |
| US-6660762-B2 | Administering porphyrin compound; respiratory system disorders | SAKALOSKY GEORGE P (US) | 2003-12-09 | — | — | US | disclosed |
| US-20030004204-A1 | Methods and compositions to treat lung diseases | SAKALOSKY GEORGE P (US) | 2003-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004204-A1 | Methods and compositions to treat lung diseases | PPOX, BPGM, CLN6 | STAT3 4868/4885STAT1 4771/4885NUDT1 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.